Squarepoint
KYTX icon

Squarepoint’s Kyverna Therapeutics KYTX Stock Holding History

Squarepoint’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-82,867
Closed -$738K – 5129
2026
Q2 		$738K Sell
82,867
-64,111
-44% -$569K ﹤0.01% 3136
2026
Q1 		$1.27M Buy
146,978
+8,110
+6% +$67.6K ﹤0.01% 2570
2025
Q4 		$1.31M Buy
+138,868
New +$1.03M ﹤0.01% 2391
2025
Q3 		– Sell
-29,730
Closed -$91.3K – 5109
2025
Q2 		$91.3K Buy
+29,730
New +$73.5K ﹤0.01% 4191
2025
Q1 		– Sell
-11,488
Closed -$43K – 5562
2024
Q4 		$43K Buy
+11,488
New +$55K ﹤0.01% 4868
2024
Q2 		– Sell
-88,423
Closed -$2.2M – 4747
2024
Q1 		$2.2M Buy
+88,423
New +$2.47M ﹤0.01% 2026

Other funds holding KYTX

Gilead Sciences
Gilead Sciences Foster City, California $1.46B AUM 71.23% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Squarepoint's KYTX Position: Q3 2026 in Review

Squarepoint sold out of Kyverna Therapeutics (KYTX) in Q3 2026, closing a stake of 82,867 shares — an estimated $738K sold.

Squarepoint first reported a position in KYTX in Q1 2024 and held it in 6 quarters. The position peaked at $2.2M in Q1 2024. 49 funds tracked by Wall St. Rank hold KYTX as of Q3 2026.

  • Squarepoint reported no remaining Kyverna Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Squarepoint sold 82,867 Kyverna Therapeutics shares in Q3 2026, an estimated $738K.
  • Squarepoint first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 6 quarters.
  • Squarepoint's Kyverna Therapeutics position peaked at $2.2M in Q1 2024.
  • 49 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.